OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune response in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapiesAug 6, 2026
Superior Efficacy and Selectivity of Novel Small-Molecule Kinase Inhibitors of T790M-Mutant EGFR in Preclinical Models of Lung CancerJul 22, 2026
YH25448, an irreversible 3rd-generation EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLCJul 22, 2026
YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study resultsJul 22, 2026
YH25448, a 3rd Generation EGFR-TKI, in Patients with EGFR-TKI-resistant NSCLC: Phase I/II Study ResultsJul 22, 2026
